SCHEMBL18227598

SCHEMBL18227598

C#Cc1cccc(C(=O)O)c1-c1ccc2sc(C)nc2c1.c1cc2cc-2c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ EIF2AK3 Q9NZJ5 1/20 0.41
▸ MAPT P10636 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.37
▸ TRPV1 Q8NER1 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ FGFR3 P22607 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ TP53 P04637 1/20 0.35
▸ DHODH Q02127 1/20 0.35
▸ LDHA P00338 1/20 0.34
▸ PIK3CG P48736 1/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18227597 0.83 NPC1 (0.45) NPC1RAB9ASMN1; SMN2EIF2AK3MAPT
SCHEMBL18227550 0.81 FFAR1 (0.41) NPC1RAB9AKDR
SCHEMBL16731663 0.78 NPC1 (0.40) NPC1RAB9ASMN1; SMN2EIF2AK3MAPT
SCHEMBL16720324 0.78 NPC1 (0.40) NPC1RAB9ASMN1; SMN2EIF2AK3MAPT
SCHEMBL18227596 0.77 NPC1 (0.44) NPC1RAB9AMAPTALDH1A1
SCHEMBL16719423 0.74 CAMKK2 (0.38) NPC1RAB9ASMN1; SMN2EIF2AK3HDAC4
SCHEMBL16719348 0.73 FABP3 (0.38) —
SCHEMBL16719666 0.72 FGFR1 (0.51) FGFR3KDR
SCHEMBL6196778 0.72 NPC1 (0.56) NPC1RAB9ASMN1; SMN2MAPTHDAC4
SCHEMBL16719872 0.71 POLB (0.46) NPC1RAB9ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246909-A1 EBNA1 Inhibitors and Methods Using Same WISTAR INST (US) 2024-07-25 — — US claimed
US-20220064112-A1 EBNA1 Inhibitors and Methods Using Same WISTAR INST (US) 2022-03-03 — — US claimed
CN-113149885-A EBNA1 inhibitors and methods of using the same 威斯塔解剖学和生物学研究所 2021-07-23 — — CN claimed
US-20180305312-A1 EBNA1 INHIBITORS AND METHODS USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-10-25 — — US claimed
US-20240246909-A1 EBNA1 Inhibitors and Methods Using Same WISTAR INST (US) 2024-07-25 — — US disclosed
US-11912659-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2024-02-27 — — US disclosed
US-20220064112-A1 EBNA1 Inhibitors and Methods Using Same WISTAR INST (US) 2022-03-03 — — US disclosed
CN-113149885-A EBNA1 inhibitors and methods of using the same 威斯塔解剖学和生物学研究所 2021-07-23 — — CN disclosed
EP-3294705-B1 EBNA1 INHIBITORS AND METHODS USING SAME WISTAR INST (US) 2021-07-21 — — EP disclosed
US-10981867-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2021-04-20 — — US disclosed
CN-107848964-B EBNA1 inhibitors and methods of using the same 威斯塔解剖学和生物学研究所 2021-03-19 — — CN disclosed
US-20200239415-A1 EBNA1 INHIBITORS AND METHODS USING SAME WISTAR INST (US) 2020-07-30 — — US disclosed
US-10442763-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2019-10-15 — — US disclosed
US-20180305312-A1 EBNA1 INHIBITORS AND METHODS USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-10-25 — — US disclosed
EP-3294705-A1 EBNA1 INHIBITORS AND METHODS USING SAME The Wistar Institute Of Anatomy And Biology (US) 2018-03-21 — — EP disclosed
WO-2016183534-A1 EBNA1 INHIBITORS AND METHODS USING SAME THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2016-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239415-A1 EBNA1 INHIBITORS AND METHODS USING SAME MLLT1, EBNA1BP2, MALT1 NPC1 525/4885RAB9A 3106/4885SMN1; SMN2 2354/4885
US-20180305312-A1 EBNA1 INHIBITORS AND METHODS USING SAME MLLT1, EBNA1BP2, MALT1 NPC1 525/4885RAB9A 3106/4885SMN1; SMN2 2354/4885
US-10981867-B2 EBNA1 inhibitors and methods using same MLLT1, EBNA1BP2, MALT1 NPC1 525/4885RAB9A 3106/4885SMN1; SMN2 2354/4885
US-20240246909-A1 EBNA1 Inhibitors and Methods Using Same MLLT1, EBNA1BP2, MALT1 NPC1 525/4885RAB9A 3106/4885SMN1; SMN2 2354/4885
US-20220064112-A1 EBNA1 Inhibitors and Methods Using Same MLLT1, EBNA1BP2, MALT1 NPC1 525/4885RAB9A 3106/4885SMN1; SMN2 2354/4885
US-11912659-B2 EBNA1 inhibitors and methods using same MLLT1, EBNA1BP2, MALT1 NPC1 525/4885RAB9A 3106/4885SMN1; SMN2 2354/4885
US-10442763-B2 EBNA1 inhibitors and methods using same MLLT1, EBNA1BP2, MALT1 NPC1 525/4885RAB9A 3106/4885SMN1; SMN2 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback